A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever.

ABSTRACT:

Background

Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This recommendation is primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago-the methodology and results of which have recently come under scrutiny. The requirement for novel therapeutics and reassessment of ribavirin is therefore urgent. However, a significant amount of work now needs to be undertaken to ensure that future trials for LF can be conducted consistently and reliably to facilitate the efficient generation of evidence.

Methodology

We convened a consultation group to establish the position of clinicians and researchers on the core components of future t

SUBMITTER: Olayinka AT 

PROVIDER: S-EPMC8769305 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature